AB-SA01: Completed Phase I enrollment

AmpliPhi completed enrollment of about 12 healthy volunteers in a double-blind, U.S. Phase I trial to evaluate topical AB-SA01 applied once daily for 3 days. Subjects will receive 108 or 109 plaque-fo...